Table 3.
Variable | With/Without PDE5i at 24 months (%) | P | Not Using PDE5i at 24 months (%) | P |
---|---|---|---|---|
Age | ||||
<60(N = 81) | 48 | 23 | ||
≥60(N = 51) | 16 | P< 0.001 | 4 | P< 0.001 |
Nerve-sparing status* | ||||
Nerves spared (N = 100) | 35 | 16 | ||
Unilateral resection (14)† | 21 | P = 0.16 | 7 | P=0.20 |
Bilateral resection (N = 3)‡ | 0 | 0 | ||
Vascular risk factor | ||||
No VRF (N = 54) | 44 | 22 | ||
≥1 VRF (N = 78) | 30 | P = 0.08 | 12 | P = 0.10 |
Note:
Fifteen subjects in this group did not have nerve-sparing status recorded.
Nine men were ≥60, 1 BTB with PDE5i.
Two men were ≥60.
BTB = back to their baseline; PDE5i = phosphodiesterase type 5 inhibitor; VRF = vascular risk factor